16:31 EDT Acrivon Therapeutics (ACRV) sees cash, equivalents funding expenses into 2Q27
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACRV:
- Acrivon Therapeutics assumed with an Overweight at Piper Sandler
- Biotech Alert: Searches spiking for these stocks today
- Acrivon Therapeutics to present data from analyses of ACR-2316 at AACR
- Acrivon Therapeutics Reports Progress in Cancer Drug Development
- Acrivon Therapeutics Appoints New Chief Medical Officer